share_log

Billionaire Beau Wrigley Faces Another Cannabis Lawsuit, This Time Worth $80M, Seeks Arbitration

Billionaire Beau Wrigley Faces Another Cannabis Lawsuit, This Time Worth $80M, Seeks Arbitration

億萬富翁博瑞格利面臨另一起大麻訴訟,這次價值8000萬美元,尋求仲裁
Benzinga Real-time News ·  2022/07/01 09:20

Billionaire William "Beau" Wrigley Jr, heir to the Wrigley chewing gum fortune, has requested arbitration in a failed Parallel deal to buy six Chicago cannabis companies. 

億萬富翁小威廉· “博” ·瑞格利箭牌口香糖財富的繼承人已要求就一項收購芝加哥六家大麻公司的平行協議進行仲裁。

Wrigley is already facing lawsuits over another failed deal – Parallel's initial public offering via an announced billion-dollar merger with Ceres Acquisition Corp (OTCQX:CERAF). At the time, Wrigley was the CEO of the cannabis company Parallel.  

箭牌已經因另一筆失敗的交易面臨訴訟—— Parallel 通過宣佈與穀神星收購公司(OTCQX: CERAF)進行數十億美元的合併,進行首次公開募股。當時,箭牌是大麻公司Parallel的首席執行官  

The two companies confirmed in October they had terminated their business combination after months of negotiations thus ending Wrigley's plans to take his MSO public. The companies did not provide a reason for calling off the merger.

兩家公司在10月證實,經過數月的談判,他們終止了業務合併,從而結束了箭牌將其MSO上市的計劃。兩家公司沒有提供取消合併的理由。

Prior to this, in April 2021, the cannabis company agreed to acquire Windy City, an Illinois-based medical and adult-use cannabis retail brand for $100 million in cash and stock.

在此之前,在 2021 年 4 月, 這家大麻公司同意以1億美元的現金和股票收購總部位於伊利諾伊州的醫療和成人用大麻零售品牌Windy City。

About a month after Parallel and Ceres dropped the deal, Wrigley resigned as CEO of the company. Quickly after the SPAC deal failed, Parallel investors sued in Florida and New York arguing they were misled regarding the financial standing of the business, wrote Green Market Report. 

在Parallel和Ceres放棄交易大約一個月後,箭牌辭去了該公司首席執行官的職務。《綠色市場報告》寫道,SPAC交易失敗後不久,Parallel投資者在佛羅里達州和紐約提起訴訟,辯稱他們在業務財務狀況方面被誤導了。

Why Did The Windy City Deal Fail? 

爲甚麼 Windy City 協議失敗了?

As per the lawsuit filed in Cook County Circuit Court, one of the obstacles to closing the deal is Wrigley's ownership. Even though he is no longer CEO, he is the largest shareholder in Parallel, according to the litigation. The problem is that his ownership stake involves at least one trust, which is forbidden under state regulations. 

根據庫克縣巡迴法院提起的訴訟,達成交易的障礙之一是箭牌的所有權。訴訟顯示,儘管他不再是首席執行官,但他是Parallel的最大股東。問題在於他的所有權涉及至少一個信託,這是州監管所禁止的。

Furthermore, it seems Parallel has not raised enough money to finalize the deal and failed to get regulatory approvals. 

此外,Parallel 似乎沒有籌集到足夠的資金來完成交易,也沒有獲得監管部門的批准。

Windy City is among a small group of businesses in Illinois with several licenses, which would enable a purchaser to step into the market with a position standing against Cresco Labs (OTCQX:CRLBF), Green Thumb Industries (OTC:GTBIF), and Verano Holdings (OTCQX:VRNOF), and others that have the maximum number of licenses legally allowed. 

Windy City是伊利諾伊州爲數不多的擁有多張許可證的企業之一,這將使購買者能夠在與之抗衡的地位進入市場克雷斯科實驗室(OTCQX: CRLBF),綠拇指工業(場外交易代碼:GTBIF),以及維拉諾控股(OTCQX: VRNOF) 以及其他具有法律允許的最大許可證數量的公司。

Wrigley is pushing to remove himself in arbitration over this broken deal by Parallel to acquire Windy City. The billionaire claims he was not a party or signatory to the purchase agreement for Chicago cannabis stores and was not acting as an agent to Parallel or a related company. "He thus is entitled to an injunction barring Defendants from maintaining arbitration proceedings against him, and a declaration that Defendants' claims against him are not arbitrable," the filing reads. 

箭牌正在推動就Parallel收購Windy City的這筆違約而在仲裁中撤職。這位億萬富翁聲稱他不是芝加哥大麻商店收購協議的當事方或簽署人,也沒有充當 Parallel 或關聯公司的代理人。文件寫道:“因此,他有權獲得禁令,禁止被告維持針對他的仲裁程序,並宣佈被告對他的索賠不可仲裁。”

"Finally, Defendants allege that Parallel is the 'alter ego' of Mr. Wrigley such that he should be personally liable for any damages arising from Defendants' claims against Parallel," according to the filing. The document also noted that Windy City's arbitration is seeking $80 million in damages. 

文件稱:“最後,被告聲稱Parallel是Wrigley先生的'另一個自我',因此他應該對被告對Parallel的索賠所產生的任何損害承擔個人責任。”該文件還指出,Windy City的仲裁正在尋求8000萬美元的賠償。

Photo: Benzinga; Source: Shutterstock

照片:Benzinga;來源:Shutterstock

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論